# CB-101

Source: https://onco.cc/drugs/cb-101/  
OnCo record `cb-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CB-101 is a three-armed antibody from XTOP Biotherapeutics that steers T cells to tumour cells carrying both ROR1 and EpCAM, in laboratory development for colon, pancreatic and lung cancers.

## Summary

CB-101 is the lead programme of XTOP Biotherapeutics, built on its CrossBody platform and described on its pipeline page as a tumour-specific and tumour-associated antigen AND-gate trispecific T-cell engager for colon, pancreatic and lung cancers. The NCI SBIR award that funds its study (1R43CA310454-01A1) names ROR1, EpCAM and CD3 as its targets. No clinical trial is registered.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: CB-101
- Modality: Trispecific antibody (T-cell engager)
- Mechanism: A trispecific T-cell engager that, according to its NCI award, binds ROR1 and EpCAM on tumour cells and CD3 on T cells; the company describes it as an AND-gate design that needs both tumour antigens present.

## Sources

- XTOP Biotherapeutics pipeline: https://www.xtopbiotherapeutics.com/pipeline/pipeline
- NIH RePORTER: 1R43CA310454-01A1: https://reporter.nih.gov/project-details/11407471

## Connected records

- technologies: [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/)
- targets: [CD3](https://onco.cc/targets/cd3/), [EpCAM](https://onco.cc/targets/epcam/), [ROR1](https://onco.cc/targets/ror1/)
- companies: [XTOP Biotherapeutics](https://onco.cc/companies/xtop-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/cb-101.json